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Abstract The Dutch Hereditary Cancer Registry was
established in 1985 with the support of the Ministry of
Health (VWS). The aims of the registry are: (1) to promote
the identification of families with hereditary cancer, (2) to
encourage the participation in surveillance programs of
individuals at high risk, (3) to ensure the continuity of
lifelong surveillance examinations, and (4) to promote
research, in particular the improvement of surveillance
protocols. During its early days the registry provided
assistance with family investigations and the collection of
medical data, and recommended surveillance when a
family fulfilled specific diagnostic criteria. Since 2000 the
registry has focused on family follow-up, and ensuring the
quality of surveillance programs and appropriate clinical
management. Since its founding, the registry has identified
over 10,000 high-risk individuals with a diverse array of
hereditary cancer syndromes. All were encouraged to
participate in prevention programmes. The registry has
published a number of studies that evaluated the outcome
of surveillance protocols for colorectal cancer (CRC) in
Lynch syndrome, as well as in familial colorectal cancer. In
2006, evaluation of the effect of registration and colono-
scopic surveillance on the mortality rate associated with
colorectal cancer (CRC) showed that the policy led to a
substantial decrease in the mortality rate associated with
CRC. Following discovery of MMR gene defects, the first
predictive model that could select families for genetic
testing was published by the Leiden group. In addition,
over the years the registry has produced many cancer risk
studies that have helped to develop appropriate surveil-
lance protocols. Hereditary cancer registries in general, and
the Lynch syndrome registry in particular, play an impor-
tant role in improving the clinical management of affected
families.
Keywords Hereditary cancer  Registry  Follow-up
system  Identification  Lynch syndrome  Cancer risk 
Surveillance
Introduction
The Dutch Hereditary Cancer Registry was established in
1985 [1, 2]. Up to 2013 the registry was financed by the
Ministry of Health (VWS), but it is now being financed by
Dutch hospitals and insurance companies. The aims of the
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registry are: (1) to promote the identification of families
with hereditary cancer, (2) to encourage high-risk indi-
viduals to participate in surveillance programs, (3) to
ensure the continuity of the surveillance examinations
which are required lifelong, and (4) to promote research, in
particular the improvement of surveillance protocols.
The approach developed by the registry was simple but
wide-ranging: we first established collaborations with all
major gastroenterology departments in the Netherlands,
and then formed a national multidisciplinary collaborative
group that consisted of physicians with an interest in
hereditary CRC. During the early years, data were col-
lected locally at each collaborating institution on previ-
ously identified families (in particular, polyposis and
Lynch syndrome families) and family investigations were
also offered. When dealing with very large families, we
organised local meetings (similar to the Family Informa-
tion Service (FIS) methods described by Lynch [3]) in
order to inform family members about the syndromes and
about surveillance options. In the 1990’s, following the
discovery of the major gene defects responsible for most of
the hereditary cancer syndromes, family cancer clinics
were established all over the country and proceeded to
offer presymptomatic testing. At that time we opened
discussions with the Dutch Association of Clinical Genetic
Centres on how tasks could be distributed between the
registry and family cancer clinics. It was agreed that the
clinical genetic centres would take responsibility for family
investigations, genetic counselling, genetic testing and
provision of up-to-date information on screening programs.
The task of the registry would be to focus on follow-up of
the families over their lifetime, and on the quality of
surveillance programs and clinical management. This
approach is schematically illustrated in Fig. 1. Since 2000,
clinical geneticists refer families with a proven mutation to
both the registry and the clinical specialist (e.g., gas-
troenterologist, gynaecologist) for surveillance. The results
of screening by the clinical specialist are shared with the
registry, and at regular intervals (1–3 years depending on
the disorder) the registry sends out surveillance reminders
to the specialists. To date, the registry has identified over
10,000 high-risk individuals with various hereditary cancer
syndromes (Table 1), all of whom were encouraged to
participate in prevention programmes.
In 2006 we carried out an evaluation of the effect of
registration, followed by surveillance. At that time 140
families with Lynch syndrome were registered, including
nearly 3000 mutation carriers and their first-degree rela-
tives. The standard mortality rate (SMR) associated with
CRC (the mortality rate associated with CRC observed in
the families relative to the mortality rate of CRC in the
general population) was calculated for three periods of
15 years, and it was found that registration together with
surveillance led to a substantial decrease in the SMR [4].
A meta-analysis of the effect of registration and
screening on the CRC mortality rate in both Lynch syn-
drome and familial adenomatous polyposis (FAP) was
recently performed by Barrow et al. [5.] The results
regarding Lynch syndrome confirmed our findings.
The initial success of the registry was mainly due to the
large numbers of families that were rapidly identified by
our highly-motivated genetic counsellors and registry
administrative staff. Next, we established successful
national and international collaborations. International
collaboration started with the launch of the International
Collaborative Group on HNPCC (ICG-HNPCC), its first
meeting organised by the registry in Amsterdam in 1990
[6]. All subsequent meetings over the first 10 years of the
collaboration were organised by the Dutch registry, toge-
ther with local organisers. In 2006 a European collabora-
tive group was established by the registry, together with
our German colleague (Gabriela Moslein).
The current chapter will address three questions: (1)
how can we identify families at risk for Lynch syndrome,
(2) what are the risks of developing CRC and other cancers,
and (3) how effective are the screening programs for CRC
and other cancers. In particular, we discuss the contribu-








Research: Evaluaon of surveillance
Fig. 1 Methodology of the registry 1985–2015
Table 1 Number of registered individuals per hereditary tumour
syndrome (2014)
Disorder N
Familial adenomatous polyposis 3700
HNPCC/Lynch Syndrome 3020
Familial CRC 550
Hereditary breast (ovarian) cancer 2700
FAMMM 2570
Hereditary prostate cancer 1005
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Identification
At the time of founding of the registry in 1985, Lynch
syndrome (LS) was still a relatively little-known disorder
and only a few families had been described in the literature,
mainly by Henry T. Lynch. When establishing a new
syndrome several criteria need to be met, including [1] an
appropriate name, [2] clinical diagnostic criteria, and [3]
ideally a known underlying genetic defect. When a gene is
identified it is important to determine which families
should be tested [4]. Finally, families that should be tested
using specific markers (MSI, see below) need to be iden-
tified [5].
In the 1980s, Lynch syndrome was referred to by many
different names such as ‘cancer family syndrome’,
‘hereditary site-specific CRC’, ‘Lynch Syndrome type 1’,
‘Lynch Syndrome type 2’, etc. [7] One of the first
achievements of the ICG-HNPCC was the proposal of a
uniform term for Lynch syndrome, ‘hereditary non-poly-
posis colorectal cancer’ (HNPCC) [6]. At the time this
name was particularly useful in clinical practice because it
specified a hereditary form of CRC that could then be
better differentiated from familial adenomatous polyposis
(FAP), already a well-known syndrome by the 1980s. The
group also proposed clinical diagnostic criteria, the well-
known Amsterdam criteria, which were particularly useful
in identifying families suitable for research [6, 8].
During the 1990s, the molecular basis of Lynch syn-
drome and all major underlying gene defects were dis-
covered within a very short period [9]. The high costs of
mutation analysis at the time meant that it was important to
select the appropriate families for genetic testing. Based on
the outcome of genetic testing of families known to the
registry, the Leiden group developed the first predictive
model that could be used for this purpose [10]. Nowadays,
several widely-used models are available [11].
In 1993, a Finnish study reported that tumours associ-
ated with LS were characterised by the presence of
microsatellite instability (MSI) [12]. This important
observation provided a new means of identifying families
with LS. Subsequently, (the Bethesda) guidelines for MSI
were developed based on the cardinal features of LS: early
age of onset of CRC, multiple tumours in one individual
and multiple family members with a tumour [13]. A major
problem was that a detailed family history was required to
evaluate whether a family complied with the Amsterdam
criteria or Bethesda guidelines. However, numerous studies
have shown that family history is often neglected in clinical
practice [14]. A new approach that solved this problem was
suggested by Hampel and co-workers—the screening of all
new CRC cases by MSI analysis (or IHC) [15]. They
performed MSI analysis (and immunohistochemical MMR
protein analysis) followed by mutation analysis of the
positive cases in a large series of unselected CRC cases. A
mutation was identified in about 2.5 % of all CRC cases, in
addition to a large number of relatives of index patients
who were found to carry a predisposing mutation.
Based on these findings the authors recommended
screening of all new CRCs for MSI or IHC, independent of
the family history. Subsequent studies confirmed these
findings and reported a detection rate of 3–4 % for MMR
gene defects in unselected CRC cases [16]. Moreover,
various studies showed that this approach was cost-effec-
tive [17], and universal screening has now been imple-
mented in many countries.
Cancer risk in Lynch syndrome
Over the years, the Dutch registry has contributed many
studies on the risk of developing cancer [18–26]. The first
of these described the tumour spectrum associated with
Lynch syndrome [22]. The Dutch registry also published
the first estimates for cancer risk in carriers with a proven
MMR gene defect [23]. In collaboration with the Omaha
registry, data were published on the risk of endometrial
cancer and extra-colonic cancer [27, 28]. The registry also
collaborated with the German HNPCC Consortium and
reported risk for extracolonic cancers evaluated in 2118
carriers, the largest series of carriers to date [29].
The largest current study on cancer risk in MSH6 car-
riers was reported by Baglietto et al. [30], a study that
included a large proportion of families contributed by the
Dutch registry. In 2015 the Leiden group, in collaboration
with the Dutch registry, described cancer risks in a large
series of PMS2 mutation carriers [31].
In Table 2, a summary is shown of the CRC and EC risk
estimates for the various gene defects [30–32]. The age of
onset of CRC and EC is delayed by about 5–10 years in
carriers of MSH6 or PMS2 mutations compared to carriers
of MLH1 or MSH2 mutations. Moreover, the risk of CRC
and EC is substantially lower in the carriers of an MSH6 or
PMS2 mutation compared to risk in carriers of other MMR
defects.
Table 2 Cancer risk in carriers of various MMR gene defects
MLH1/MSH2 MSH6 PMS2
CRC
Mean age (years) 45 56 52
Risk 70 years (M/F) 53/33 % 22/10 % 19/11 %
MLH1/MSH2* MSH6 PMS2
EC
Mean age (years) 45 52 55
Risk 70 years (F) 44 % 26 % 12 %
* EPCAM 12 %
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Risk estimates for extra-colonic cancer development are
summarized in Table 3 [16, 29–35]. The data show that
MSH6 mutation carriers have the lowest risk for the non-
CRC and non-endometrial cancers. MSH2 and MLH1
mutation carriers have the highest risk estimates. Infor-
mation in the literature on cancer risk for carriers of a
PMS2 mutation is limited and only estimates of relative
risk (RR) are available.
In conclusion, diverse studies have consistently shown a
substantial difference in cancer risk associated with the
various gene defects. Consequently, carriers of an MMR
defect require tailored management depending of the
underlying gene defect. To ensure that these carriers
receive appropriate management, it has been suggested that
the underlying gene defect should be included in the name
of the syndrome (e.g. MLH1-Lynch syndrome) [36].
Lynch syndrome surveillance
In 1990, the ICG-HNPPC recommended a surveillance
interval of 2–3 years between colonoscopies. Five years
later, the Dutch registry identified six patients who devel-
oped an (interval) cancer within 2–3 years of a normal
colonoscopy [37]. During the same period, studies by
Henry Lynch, Steven Lanspa and Jeremy Jass also indi-
cated that carcinogenesis (adenoma-carcinoma sequence)
in Lynch syndrome was accelerated [38, 39]. This insight
has since led to a shorter screening interval and 1–2 years
is now recommended.
In 2010, the effectiveness of this approach was evalu-
ated using data from the Dutch registry. It was found that
the risk of developing an interval cancer was relatively
low: 6 % after 10 years of follow-up [40]. Moreover, most
screen-detected tumours were early (stage 1 and 2) cancers.
The type of gene defect and the current age of the high-risk
individual were found to influence the risk of developing
an interval CRC. An MSH6 mutation and age\40 years
was associated with a (albeit non-significant) lower risk.
Based on these findings, up to age 40 a 2-year interval can
be recommended for carriers of an MLH1 or MSH2
mutation, with a more intensive program (interval
1–2 years) from age 40 years. In carriers of an MSH6
mutation or PMS2 mutation, an intensive protocol
(1–2 years) may be recommended after age 50. A recent
study, presented at the InSiGHT meeting 2015 in Sao
Paulo, evaluated the effect of the length of the screening
interval on survival and the cumulative incidence of CRC.
The investigators collected data on almost 1000 carriers of
an MLH1 mutation, half of which were from Finland where
a 2–3 year interval is advised, with the other half collected
from various European countries where 1–2 years between
examinations is the generally recommended interval. The
results showed that survival was improved in individuals
who developed an interval cancer (although non-signifi-
cant) during the shorter (1–2 year) interval. However, one
interesting finding was that cumulative CRC incidence was
significantly lower in Finland (despite the 2–3 year inter-
val) compared to other countries. One explanation might be
that the overall risk of developing CRC in the general
population is substantially lower in Finland compared to
other countries.
A summary of the prevention program for Lynch syn-
drome patients is shown in Table 4. Unfortunately, the
value of surveillance for most cancers (e.g., endometrium,
urinary tract, gastric cancer, small bowel cancer) associated
with Lynch syndrome is unknown.
Most guidelines therefore recommend screening for
these particular cancers within a research setting or in those
individuals whose screening results are collected by a
hereditary cancer registry.
Table 3 Summary of extra-
colonic cancer risk for
respective gene defect
MLH1* (%) MSH2* (%) MSH6* (%) PMS2
Urinary tract 1–3 8–10 0–1 RR renal pelvis: 50
Ovary 11 10 1 RR 12
Gastric 8 2–9 \4 RR 0
Small bowel 5 3 0 RR 115
Prostate – 17 – RR 1.7
Biliary/pancreatic 3 4 0 –
Brain 1 4 0 RR 2.7
* Life time risk by age 70
Table 4 Prevention program in Lynch Syndrome
Surveillance
MLH1: CRC, EC/OC
MSH2: CRC, EC/OC, urinary tract
MSH6: CRC, EC/OC
PMS2: CRC, EC/OC
Assessment of H. Pylori (biopsy, faeces, serology)
Discuss options for prophylactic surgery (uterus, ovaries)
General recommendations: no smoking, BMI\ 25
CRC colorectal cancer, EC endometrial cancer, OC ovarian cancer
432 H. F. A. Vasen et al.
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An example of this type of study is a recent report on the
value of videocapsule endoscopy for the early detection of
small bowel cancer. In this study a total of 200 mutation
carriers underwent videocapsule endoscopy (VCE), which
resulted in the detection of only one duodenal cancer and one
duodenal adenoma [41]. One patient developed a duodenal
cancer 7 months after a negative VCE. Regrettably, the
outcome does not allow conclusions to be drawn on the value
of VCE in the surveillance of small bowel cancer.
There is general agreement that the option of prophy-
lactic surgery (hysterectomy and bilateral salpingo-
oophorectomy) for mutation carriers from age 40 and with
a complete family history should be discussed, dependent
on the underlying gene defect. Finally, recommendations
on lifestyle factors and nutrition (avoid smoking, keep BMI
below 25) should be provided [42–44].
Surveillance of familial colorectal cancer
An important question is which surveillance program
should be recommended for families with clustering of
CRC but without evidence of MMR deficiency. Familial
CRC may be subdivided into three categories: (1) familial
colorectal cancer syndrome type X—these include families
that comply with the Amsterdam criteria but without evi-
dence of MMR deficiency [45], (2) late-onset familial
clustering of colorectal cancer—families similar to [1] but
all CRC cases diagnosed above the age of 50 years [46],
and (3) familial CRC ss (sensu strictu)—families with one
first-degree relative with CRC\50 years or two first-de-
gree relatives with CRC.
A team of investigators from St Mark’s hospital evalu-
ated the effectiveness of surveillance (3–5 year interval)
for the first two categories of familial CRC in a large series
(approx. 1000) of high-risk family members [47]. They
showed that the risk of developing CRC under surveillance
was low (\5 %) and the risk for high-risk adenoma was
also relatively low (\20 %).
In the Netherlands, a randomized controlled trial in
familial colorectal cancer (category 3) was recently com-
pleted [48]. The aims were: (1) to assess the appropriate
surveillance interval, and (2) to identify risk factors for the
development of AAP at follow-up. A total of 550 individ-
uals at risk for familial colorectal cancer participated in the
study. The participants were subdivided according to the
findings at the baseline colonoscopy. Patients with 0–2
adenomas were randomized into two groups, A and B.
Group A underwent colonoscopy after 6 years and group B
at 3 and 6 years. The endpoint of the study was the presence
of an advanced adenomatous polyp (AAP). The results
showed that the frequency of AAP at 6-year follow-up was
two-fold higher (but not significant) compared to the fre-
quency after 3 years. The presence of AAP at baseline was
found to be a significant predictive factor for the develop-
ment of AAP at follow-up. After correction for AAP at
baseline, the difference in the frequency of AAP between
group A and group B was significant. However, the absolute
risk of developing AAP after 6 years was relatively low
(6.9 %). Moreover, none of the participants in group A
instead of B developed CRC. Therefore, we consider an
interval of 6 years to be safe. However, when an AAP is
detected at baseline the colonoscopy should be repeated
after 3 years.
Conclusion
The studies conducted by the Dutch registry have con-
tributed substantially to the understanding and appropriate
care of Lynch syndrome patients. A major step forward in
the identification of Lynch syndrome families has been the
use of universal screening of all new cases of CRC and
EC\ age 70 by MSI analysis or immunohistochemical
analysis of the MMR proteins; hopefully this approach will
eventually allow the detection of all Lynch syndrome cases.
In the coming years, the use of universal screening should
be evaluated for other cancers associated with Lynch syn-
drome (ovarian cancers, small bowel cancer, gastric cancer,
urinary tract cancer, and sebaceous tumours).
All studies that have evaluated cancer risk in Lynch
syndrome patients have shown substantial differences in
risk between carriers of MLH1 or MSH2 mutations and
those with MSH6 or PMS2 mutations. This has important
implications for the surveillance protocols used in these
families. In order to facilitate personalized management,
we propose that the gene defect is included with the name
of the syndrome (e.g., MSH2-Lynch syndrome, etc.) [36].
The currently recommended surveillance interval
(1–2 years) for Lynch syndrome families appears to be safe.
Future studies should evaluate the value of surveillance of
other LS-associated cancers. Because there is no evidence of
accelerated carcinogenesis in families with familial col-
orectal cancer, an interval of 3–6 years is generally advised.
The establishment of the ICG-HNPCC had led to
worldwide collaboration in the field of Lynch syndrome.
Henry Lynch, the first chairman of the group, was the
motor behind all these activities. He has been a constant
inspiration, an example and a friend to all researchers and
healthcare providers in the field.
Open Access This article is distributed under the terms of the
Creative Commons Attribution 4.0 International License (http://crea
tivecommons.org/licenses/by/4.0/), which permits unrestricted use,
distribution, and reproduction in any medium, provided you give
appropriate credit to the original author(s) and the source, provide a
link to the Creative Commons license, and indicate if changes were
made.
Hereditary cancer registries improve the care of patients with a genetic predisposition to… 433
123
References
1. Vasen HF, Griffioen G, Lips CJ, Struyvenberg A, Van Slooten
EA (1990) Screening of families predisposed to cancer devel-
opment in The Netherlands. Anticancer Res 10(2B):555–563
2. Vasen HF, Griffioen G, Lips CJ, Van Slooten EA (1988) The
value of screening and the national registration of hereditary
tumors. Ned Tijdschr Geneeskd 132(35):1609–1612
3. Lynch HT (2001) Family information service and hereditary
cancer. Cancer 91(4):625–628
4. de Jong AE, Hendriks YM, Kleibeuker JH, de Boer SY, Cats A,
Griffioen G et al (2006) Decrease in mortality in Lynch syndrome
families because of surveillance. Gastroenterology 130(3):665–671
5. Barrow P, Khan M, Lalloo F, Evans DG, Hill J (2013) Systematic
review of the impact of registration and screening on colorectal
cancer incidence and mortality in familial adenomatous polyposis
and Lynch syndrome. Br J Surg 100(13):1719–1731
6. Vasen HF, Mecklin JP, Khan PM, Lynch HT (1991) The inter-
national collaborative group on hereditary non-polyposis col-
orectal cancer (ICG-HNPCC). Dis Colon Rectum 34(5):424–425
7. Boland CR (2005) Evolution of the nomenclature for the hered-
itary colorectal cancer syndromes. Fam Cancer 4(3):211–218
8. Vasen HF, Watson P, Mecklin JP, Lynch HT (1999) New clinical
criteria for hereditary nonpolyposis colorectal cancer (HNPCC,
Lynch syndrome) proposed by the international collaborative
group on HNPCC. Gastroenterology 116(6):1453–1456
9. Peltomaki P (2005) Lynch syndrome genes. Fam Cancer 4(3):
227–232
10. Wijnen JT, Vasen HF, Khan PM, Zwinderman AH, van der KH,
Mulder A et al (1998) Clinical findings with implications for
genetic testing in families with clustering of colorectal cancer.
N Engl J Med 339(8):511–518
11. Kastrinos F, Balmana J, Syngal S (2013) Prediction models in
Lynch syndrome. Fam Cancer 12(2):217–228
12. Aaltonen LA, Peltomaki P, Leach FS, Sistonen P, Pylkkanen L,
Mecklin JP et al (1993) Clues to the pathogenesis of familial
colorectal cancer. Science 260(5109):812–816
13. Rodriguez-Bigas MA, Boland CR, Hamilton SR, Henson DE,
Jass JR, Khan PM et al (1997) A national cancer institute
workshop on hereditary nonpolyposis colorectal cancer syn-
drome: meeting highlights and Bethesda guidelines. J Natl Can-
cer Inst 89(23):1758–1762
14. van Dijk DA, Oostindier MJ, Kloosterman-Boele WM, Krijnen P,
Vasen HF (2007) Family history is neglected in the work-up of
patients with colorectal cancer: a quality assessment using cancer
registry data. Fam Cancer 6(1):131–134
15. Hampel H, Frankel WL, Martin E, Arnold M, Khanduja K,
Kuebler P et al (2005) Screening for the Lynch syndrome
(hereditary nonpolyposis colorectal cancer). N Engl J Med
352(18):1851–1860
16. Vasen HF, Blanco I, Aktan-Collan K, Gopie JP, Alonso A, Aretz
S et al (2013) Revised guidelines for the clinical management of
Lynch syndrome (HNPCC): recommendations by a group of
European experts. Gut 62(6):812–823
17. Mvundura M, Grosse SD, Hampel H, Palomaki GE (2010) The
cost-effectiveness of genetic testing strategies for Lynch syn-
drome among newly diagnosed patients with colorectal cancer.
Genet Med 12(2):93–104
18. Hendriks YM, Wagner A, Morreau H, Menko F, Stormorken A,
Quehenberger F et al (2004) Cancer risk in hereditary nonpoly-
posis colorectal cancer due to MSH6 mutations: impact on
counseling and surveillance. Gastroenterology 127(1):17–25
19. Hendriks YM, Jagmohan-Changur S, van der Klift HM, Morreau
H, van PM, Tops C et al (2006) Heterozygous mutations in PMS2
cause hereditary nonpolyposis colorectal carcinoma (Lynch
syndrome). Gastroenterology 130(2):312–322
20. Quehenberger F, Vasen HF, van Houwelingen HC (2005) Risk of
colorectal and endometrial cancer for carriers of mutations of the
hMLH1 and hMSH2 gene: correction for ascertainment. J Med
Genet 42(6):491–496
21. ten Kate GL, Kleibeuker JH, Nagengast FM, Craanen M, Cats A,
Menko FH et al (2007) Is surveillance of the small bowel indi-
cated for Lynch syndrome families? Gut 56(9):1198–1201
22. Vasen HF, Offerhaus GJ, Hartog Jager FC, Menko FH, Nagen-
gast FM, Griffioen G et al (1990) The tumour spectrum in
hereditary non-polyposis colorectal cancer: a study of 24 kindreds
in the Netherlands. Int J Cancer 46(1):31–34
23. Vasen HF, Wijnen JT, Menko FH, Kleibeuker JH, Taal BG,
Griffioen G et al (1996) Cancer risk in families with hereditary
nonpolyposis colorectal cancer diagnosed by mutation analysis.
Gastroenterology 110(4):1020–1027
24. Vasen HF, Sanders EA, Taal BG, Nagengast FM, Griffioen G,
Menko FH et al (1996) The risk of brain tumours in hereditary
non-polyposis colorectal cancer (HNPCC). Int J Cancer 65(4):
422–425
25. Vasen HF, Morreau H, Nortier JW (2001) Is breast cancer part of
the tumor spectrum of hereditary nonpolyposis colorectal cancer?
Am J Hum Genet 68(6):1533–1535
26. Vasen HF, Stormorken A, Menko FH, Nagengast FM, Kleibeuker
JH, Griffioen G et al (2001) MSH2 mutation carriers are at higher
risk of cancer than MLH1 mutation carriers: a study of hereditary
nonpolyposis colorectal cancer families. J Clin Oncol 19(20):
4074–4080
27. Watson P, Lynch HT (1993) Extracolonic cancer in hereditary
nonpolyposis colorectal cancer. Cancer 71(3):677–685
28. Watson P, Vasen HF, Mecklin JP, Jarvinen H, Lynch HT (1994)
The risk of endometrial cancer in hereditary nonpolyposis col-
orectal cancer. Am J Med 96(6):516–520
29. Engel C, Loeffler M, Steinke V, Rahner N, Holinski-Feder E,
Dietmaier W et al (2012) Risks of less common cancers in proven
mutation carriers with lynch syndrome. J Clin Oncol 30(35):
4409–4415
30. Baglietto L, Lindor NM, Dowty JG, White DM, Wagner A,
Gomez Garcia EB et al (2010) Risks of Lynch syndrome cancers
for MSH6 mutation carriers. J Natl Cancer Inst 102(3):193–201
31. ten Broeke SW, Brohet RM, Tops CM, van der Klift HM, Vel-
thuizen ME, Bernstein I et al (2015) Lynch syndrome caused by
germline PMS2 mutations: delineating the cancer risk. J Clin
Oncol 33(4):319–325
32. Barrow E, Hill J, Evans DG (2013) Cancer risk in Lynch Syn-
drome. Fam Cancer 12(2):229–240
33. Barrow E, Robinson L, Alduaij W, Shenton A, Clancy T, Lalloo
F et al (2009) Cumulative lifetime incidence of extracolonic
cancers in Lynch syndrome: a report of 121 families with proven
mutations. Clin Genet 75(2):141–149
34. Bonadona V, Bonaiti B, Olschwang S, Grandjouan S, Huiart L,
Longy M et al (2011) Cancer risks associated with germline
mutations in MLH1, MSH2, and MSH6 genes in Lynch syn-
drome. JAMA 305(22):2304–2310
35. Watson P, Vasen HF, Mecklin JP, Bernstein I, Aarnio M, Jarvi-
nen HJ et al (2008) The risk of extra-colonic, extra-endometrial
cancer in the Lynch syndrome. Int J Cancer 123(2):444–449
36. Vasen HF, Tomlinson I, Castells A (2015) Clinical management
of hereditary colorectal cancer syndromes. Nat Rev Gastroenterol
Hepatol 12(2):88–97
37. Vasen HF, Nagengast FM, Khan PM (1995) Interval cancers in
hereditary non-polyposis colorectal cancer (Lynch syndrome).
Lancet 345(8958):1183–1184
434 H. F. A. Vasen et al.
123
38. Lanspa SJ, Jenkins JX, Cavalieri RJ, Smyrk TC, Watson P, Lynch
J et al (1994) Surveillance in Lynch syndrome: how aggressive?
Am J Gastroenterol 89(11):1978–1980
39. Jass JR, Stewart SM, Stewart J, Lane MR (1994) Hereditary non-
polyposis colorectal cancer–morphologies, genes and mutations.
Mutat Res 310(1):125–133
40. Vasen HF, Abdirahman M, Brohet R, Langers AM, Kleibeuker
JH, van KM et al (2010) One to 2-year surveillance intervals
reduce risk of colorectal cancer in families with Lynch syndrome.
Gastroenterology 138(7):2300–2306
41. Haanstra JF, Al-Toma A, Dekker E, Vanhoutvin SA, Nagengast
FM, Mathus-Vliegen EM et al (2015) Prevalence of small-bowel
neoplasia in Lynch syndrome assessed by video capsule endo-
scopy. Gut 64(10):1578–1583
42. Botma A, Nagengast FM, Braem MG, Hendriks JC, Kleibeuker
JH, Vasen HF et al (2010) Body mass index increases risk of
colorectal adenomas in men with Lynch syndrome: the GEO-
Lynch cohort study. J Clin Oncol 28(28):4346–4353
43. Botma A, Vasen HF, Van Duijnhoven FJ, Kleibeuker JH,
Nagengast FM, Kampman E (2013) Dietary patterns and col-
orectal adenomas in Lynch syndrome: the GEOLynch cohort
study. Cancer 119(3):512–521
44. Winkels RM, Botma A, Van Duijnhoven FJ, Nagengast FM,
Kleibeuker JH, Vasen HF et al (2012) Smoking increases the risk
for colorectal adenomas in patients with Lynch syndrome. Gas-
troenterology 142(2):241–247
45. Lindor NM, Rabe K, Petersen GM, Haile R, Casey G, Baron J
et al (2005) Lower cancer incidence in Amsterdam-I criteria
families without mismatch repair deficiency: familial colorectal
cancer type X. JAMA 293(16):1979–1985
46. Vasen HF, Taal BG, Griffioen G, Nagengast FM, Cats A, Menko
FH et al (1994) Clinical heterogeneity of familial colorectal
cancer and its influence on screening protocols. Gut 35(9):1262–
1266
47. Mesher D, Dove-Edwin I, Sasieni P, Vasen H, Bernstein I, Royer-
Pokora B et al (2014) A pooled analysis of the outcome of
prospective colonoscopic surveillance for familial colorectal
cancer. Int J Cancer 134(4):939–947
48. Hennink SD, van der Meulen-de Jong AE, Wolterbeek R, Cro-
bach AS, Becx MC, Crobach WF et al (2015) Randomized
comparison of surveillance intervals in familial colorectal cancer.
J Clin Oncol 33(35):4188–4193
Hereditary cancer registries improve the care of patients with a genetic predisposition to… 435
123
